DARE
Dare Bioscience, Inc. (DARE) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Negative cash conversion cycle indicates working-capital efficiency versus peers, because suppliers effectively finance operations and reduce near-term cash needs.
Net debt to EBITDA remains modest, which supports balance-sheet flexibility relative to more levered peers and lowers refinancing pressure.
Return on invested capital is only slightly negative, suggesting capital deployment is not deeply impaired versus weaker peers, though it still trails value-creating operators.
Weaknesses
Return on invested capital is negative, showing the business is not yet earning its cost of capital and lagging profitable peers on structural value creation.
Current and quick ratios are below 1.0, which leaves less liquidity headroom than stronger peers and increases dependence on uninterrupted operating cash flow.
The absence of disclosed margin data limits transparency, but the available profitability signals still point to a weaker earnings profile than established peers.
Opportunities
Improving operating discipline could convert the negative cash conversion cycle into a durable funding advantage, widening the gap versus peers with slower working-capital turns.
If capital allocation improves, even modest ROIC gains would materially strengthen competitive positioning because current returns are near breakeven rather than deeply impaired.
Greater disclosure and execution consistency could narrow the valuation and credibility gap versus peers, especially if future filings show sustained profitability improvement.
Threats
Persistent negative ROIC threatens long-term competitiveness, because peers with positive returns can reinvest more aggressively and compound market share faster.
Sub-1.0 liquidity ratios increase vulnerability to demand shocks or funding tightness, especially versus peers with larger current asset buffers.
If working-capital benefits reverse, the company could lose a key relative advantage, exposing it to peers with stronger cash generation and balance-sheet resilience.
Overall Score
DARE’s structural positioning versus peers is weak overall, as modest working-capital efficiency and limited leverage are outweighed by negative ROIC and thin liquidity.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Dare Bioscience, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
